Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 3Advanced Solid Tumor 3Stomach Neoplasms 2Lung Neoplasms 2Cholangiocarcinoma 2Advanced Lung Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous NSCLC 1Solid Tumor 1SCLC 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Diseases 1High-Risk Resectable NSCLC 1Gastrointestinal Diseases 1Esophageal Diseases 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

toripalimab 2sintilimab 2Surveys and Questionnaires 1Pemetrexed 1Paclitaxel 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Lung Cancer × sintilimab × Clear all
NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
19 enrolled
Thoracic

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
42 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡